If you didn't make it to Sweden for this important MS meeting, don’t worry. We've distilled key presentations from ECTRIMS for you in an easy to review audio format, also downloadable to your iPod!
In this program, we focus our discussion on presentations related to the following topics:
- Discontinuation of natalizumab therapy
- Utility of natalizumab following failure of first line therapy
- Shift in thinking about therapeutic goals for disease-modifying agents
- Relevance of JCV antibodies
- New data related to CCSVI
- Neuroprotection of evolving immunological therapies